Skip to main content
News > News > Open Therapeutics Trending with Academia and Professionals

Open Therapeutics Trending with Academia and Professionals

June 4, 2015. University of Oxford, Structural Genomics Consortium published a paper in PLOS Biology titled

Open Access Target Validation Is a More Efficient Way to Access Drug Discovery (CC By Wen Hwa Lee).


June 16, 2015. Deloitte released a series of Open Innovation papers including:

Executing an open innovation model – Cooperation is key to competition for biopharmaceutical companies.

Health Care Current: June 16, 2015. Building an open innovation approach to R&D.


To comment, please visit: Open Therapeutics (CC BY Jin Kong – June 18, 2015)

We Believe

Open Therapeutics crowdsources orphan and dormant therapeutic intellectual properties (IP) to scientists around the world. The goal is advancing research that ordinarily has not generated a public value or been recognized. This approach particularly helps underserved scientists to collaborate with their more financially capable colleagues.

How open science helps researchers succeed:

Open access, open data, open source, and other open scholarship practices are growing in popularity and necessity. However, widespread adoption of these practices has not yet been achieved. One reason is that researchers are uncertain about how sharing their work will affect their careers.

The review of the literature demonstrates that open science is associated with increases in citations, media attention, potential collaborators, job opportunities, and funding opportunities. These findings are evidence that open science practices bring significant benefits to researchers relative to more traditional closed practices.

Secured By miniOrange